VitaGraft Kidney's Ability to Differentiate ABMR and IgAN in Kidney Transplant Patients

OncoCyte, Corp. (Nasdaq: OCX), a precision diagnostics company, has recently released new data that demonstrates the effectiveness of VitaGraft Kidney in aiding physicians in treating kidney transplant patients with greater precision. The study focused on differentiating between two common causes of premature graft failure: antibody-mediated rejection (ABMR) and recurrent IgA nephropathy (IgAN)...

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 26.
  • textsms

IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

IntelGenx Corp. has recently announced a groundbreaking research collaboration with Karolinska University Hospital. The focus of this collaboration is to explore the potential of using Montelukast VersaFilm® as a treatment for Parkinson's Disease. Led by the esteemed Professor Per Svenningsson, an expert in clinical neuroscience, this study will delve into the efficacy of IntelGenx's innovative ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 26.
  • textsms

Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours

Crescendo Biologics, a clinical stage immuno-oncology company, has secured an additional $32 million in funding. This capital infusion was made possible through the support of all major existing investors and new investor Kreos Capital. In conjunction with this exciting news, Crescendo has announced its plans to expand the Phase 1b trial of their lead program CB307 in PSMA+ solid tumors by intro..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms

Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus

Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus Published: Jul 24, 2023 In an exciting development, Orthogon Therapeutics LLC, a leading player in the field of antiviral therapeutics, has achieved a significant breakthrough. The company's flagship molecule has successfully completed acute toxicity studies, marking a majo..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Quince Therapeutics, a biotechnology company dedicated to acquiring, developing, and bringing innovative therapeutics to market, has recently announced its agreement to acquire EryDel SpA, a late-stage biotech company. This acquisition will involve an upfront exchange of stocks and potential cash payments based on future milestones. EryDel has made significant advancements in the field with thei..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms

DiaCarta Partners with HMC/HML for Lab Development Test Validations and Compliances in the US Market

DiaCarta Inc., a leading molecular diagnostic test developer for cancer and infectious diseases, has announced a strategic partnership with Hopkins MedTech Compliance (HMC) and Hopkins MedTech Lab Services (HML) to address the regulatory compliance and laboratory developed test (LDT) validation needs in the United States. This collaboration aims to provide support to companies that have develope..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms

Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

advantage of their expertise in cancer immunotherapy. The Phase 1 study on VAC2, a potential treatment for advanced non-small cell lung cancer (NSCLC), has yielded promising results. In this study, five out of eight patients experienced immune-related stable disease as their best response. This is a significant finding, as it indicates that the treatment has the potential to stabilize the progre..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms

CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC

CG Oncology Inc. has successfully completed the enrollment of patients in their BOND-003 Phase 3 monotherapy study. This study aims to evaluate the effectiveness of cretostimogene grenadenorepvec as a potential treatment for high-risk non-muscle invasive bladder cancer (NMIBC) patients who do not respond to Bacillus Calmette-Guerin (BCG). The BOND-003 study has enrolled a total of 110 patients w..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms

Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences (NASDAQ: ENVB) has announced positive findings from preclinical studies that support the metabolic profile of its leading candidate, EB-373. The absorption, distribution, metabolism, and excretion (ADME) as well as toxicology assays have demonstrated rapid conversion of EB-373 to the active metabolite psilocin. These results are consistent with previous animal pharmacokinetic..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms

Nectero Medical Receives FDA Clearance of IND Application to Initiate Phase II/III Clinical Trial of Nectero EAST® System for Treatment of Small- to Mid-Sized Abdominal Aortic Aneurysms

Nectero Medical has received FDA clearance to begin a Phase II/III clinical trial for their Nectero EAST® System, which aims to treat small- to mid-sized abdominal aortic aneurysms. &nbsp In an exciting development, Nectero Medical, a clinical-stage biotechnology company focused on improving the lives of patients with aneurysmal disease, announced that they have been granted Investigational New ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms